Overview

This trial is active, not recruiting.

Condition chronic myeloid leukemia (cml) with philadelphia chromosome-positive (ph+)
Treatment imatinib mesylate
Phase phase 2
Sponsor Renato Melaragno
Start date February 2011
End date June 2013
Trial size 20 participants
Trial identifier NCT01221376, CSTI571ABR23T

Summary

The purpose of this study is to evaluate the hematological, cytogenetic and molecular response to continuous-use of Imatinib in children with CML Ph+.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
imatinib mesylate Glivec, MI
Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.

Primary Outcomes

Measure
Evaluate the complete cytogenetic response with continuous-use of Imatinib.
time frame: Up to 12 months

Secondary Outcomes

Measure
Evaluate the response to continuous-use of Imatinib and the toxicity and tolerability in children with CML Ph+.
time frame: Up to 24 months

Eligibility Criteria

Male or female participants up to 18 years old.

Inclusion Criteria: 1. Diagnose: suspected CML (hematology and/or myelogram and/or immunophenotyping and/or Leukocyte alkaline phosphatase [LAP]) to be confirmed, after, by cytogenetic and/or molecular biology. OBS: only CML Ph+ newly-diagnose in chronic or accelerate phase; resistant CML Ph+ to Interferon α (INF-α), Hydroxyurea and/or low-dose ARA-C in chronic or accelerate phase; CML Ph+ with cytogenetic relapse after BMT, that didn't use Imatinib previously, in chronic or accelerate phase. 2. Female patients of childbearing age, should have pregnancy test (blood βhCG) performed before treatment initiation. Effective contraception must be used. Pregnant women won't be included. 3. Karnofsky and Lansky scale: ≥40. 4. Life expectation > 8 weeks. 5. Laboratory: renal function (serum creatinine ≤ 1,5 x ULN and/or Clearance ≥70 ml/min/1,73m2), hepatic function (total bilirubin ≤ 1,5 x ULN, TGP < 3 x ULN and albumin > 2 g/dl. 6. CNS toxicity ≤ II 7. Cardiac function: normal ejection fraction. 8. Signed ICF by child legal responsible. Exclusion Criteria: 1. Patient receiving any other tyrosine kinase inhibitor (TKI). 2. Pregnant patient or breastfeeding. 3. Patient considered incapable to follow purposed treatment. 4. Patients with molecular relapsed. 5. Medications: - Colony stimulating: it cannot be administered at least 1 week before treatment. - Anticonvulsants: Imatinib is metabolized by P-450 enzyme, thereby subject cannot receive drug that activates the P-450 system. The anticonvulsants allowed are valproic acid and benzodiazepines. - Anticoagulants: The use of warfarin (Marevan) is not allowed. If anticoagulant is needed, low-molecular-weight heparin (LMWH) can be used. Avoid anticoagulants with platelets < 50000. - INF-Α 48h before D1. - Hydroxyurea 24h before D1. - ARA-C doses >100 mg/m2 for 5-7 days, 14 days before D1. - Anthracyclines, Mitoxantrone or Etoposide 21 days before D1. - Any other chemotherapeutic agent 28 days before D1. - Hematopoietic Cell Transplantation (HCT) 6 weeks before D1.

Additional Information

Official title Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)
Trial information was received from ClinicalTrials.gov and was last updated in March 2013.
Information provided to ClinicalTrials.gov by Hospital Santa Marcelina.